Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial

Zev A. Wainberg, Jason M. Link, Alykhan Premji, Serena Zheng, Michael Srienc, McKensie Hammons, Shineui E. Kim, Luyi Li, Zeyu Liu, Olga Tsvetkova, Evan R. Abt, Lee Rosen, Stephen Kim, Jonathan King, O. Joe Hines, Mark Girgis, Saeed Sadeghi, Olga Olevsky, Deborah Wong, Lisa Yonemoto, Ann Marie Siney, Kim Kelly, Christine Kivork, Chi-Hong Tseng, Caius G. Radu, David W. Dawson, Timothy R. Donahue

Open source

DOI: 10.1038/s41467-026-68976-2
Published: 2026-01-31
Container: Nature Communications
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-68976-2,
  title = {Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial},
  author = {Zev A. Wainberg and Jason M. Link and Alykhan Premji and Serena Zheng and Michael Srienc and McKensie Hammons and Shineui E. Kim and Luyi Li and Zeyu Liu and Olga Tsvetkova and Evan R. Abt and Lee Rosen and Stephen Kim and Jonathan King and O. Joe Hines and Mark Girgis and Saeed Sadeghi and Olga Olevsky and Deborah Wong and Lisa Yonemoto and Ann Marie Siney and Kim Kelly and Christine Kivork and Chi-Hong Tseng and Caius G. Radu and David W. Dawson and Timothy R. Donahue},
  year = {2026},
  journal = {Nature Communications},
  doi = {10.1038/s41467-026-68976-2},
  url = {https://doi.org/10.1038/s41467-026-68976-2}
}

RIS

TY  - JOUR
TI  - Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial
AU  - Zev A. Wainberg
AU  - Jason M. Link
AU  - Alykhan Premji
AU  - Serena Zheng
AU  - Michael Srienc
AU  - McKensie Hammons
AU  - Shineui E. Kim
AU  - Luyi Li
AU  - Zeyu Liu
AU  - Olga Tsvetkova
AU  - Evan R. Abt
AU  - Lee Rosen
AU  - Stephen Kim
AU  - Jonathan King
AU  - O. Joe Hines
AU  - Mark Girgis
AU  - Saeed Sadeghi
AU  - Olga Olevsky
AU  - Deborah Wong
AU  - Lisa Yonemoto
AU  - Ann Marie Siney
AU  - Kim Kelly
AU  - Christine Kivork
AU  - Chi-Hong Tseng
AU  - Caius G. Radu
AU  - David W. Dawson
AU  - Timothy R. Donahue
PY  - 2026
JO  - Nature Communications
DO  - 10.1038/s41467-026-68976-2
UR  - https://doi.org/10.1038/s41467-026-68976-2
ER  -

APA

Wainberg, Z. A., Link, J. M., Premji, A., Zheng, S., Srienc, M., Hammons, M., Kim, S. E., Li, L., Liu, Z., Tsvetkova, O., Abt, E. R., Rosen, L., Kim, S., King, J., Hines, O. J., Girgis, M., Sadeghi, S., Olevsky, O., Wong, D., Yonemoto, L., Siney, A. M., Kelly, K., Kivork, C., Tseng, C., Radu, C. G., Dawson, D. W., & Donahue, T. R. (2026). Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Nature Communications. https://doi.org/10.1038/s41467-026-68976-2

Source records

crossref · retrieved 2026-09-25T21:46:08.655Z